3-Day malaria cure could transform treatment
NCT ID NCT07468526
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a shorter, higher-dose course of primaquine to cure vivax malaria and prevent it from coming back. Current treatments take too long, so a 3-day course could make it easier for patients to complete therapy. The trial involves over 1,000 people aged 5 and older with normal G6PD enzyme levels. Researchers will check if the short course is safe and effective in stopping malaria relapse for up to 6 months.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALARIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Aga Khan University, Karachi
Karachi, Thatta, Pakistan
-
Arba Minch University
Arba Minch, Arba Minch, Ethiopia
-
Jimma University
Jimma, Jimma, Ethiopia
-
Papua New Guinea Institute of Medical Research
Port Moresby, Magang, Papua New Guinea
-
Universitas Sumatera
Bandar Lampung, Lampung, Indonesia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill make your blood deadly to malaria mosquitoes?
- Can a new vaccine stop malaria in its tracks?
- Can a new malaria vaccine slash childhood cases? a massive real-world test seeks answers.
- One shot, six months of malaria shield? a new trial tests a powerful antibody in children
- School health rooms and trained teachers: a new hope for Zambia's children?
- Experimental malaria vaccine aims to block parasite growth